Nifty
Sensex
:
:
9630.00
31290.74
-3.60 (-0.04%)
7.10 (0.02%)

Pharmaceuticals & Drugs

Rating :
51/99   (View)

BSE: 532523 | NSE: BIOCON

332.10
-5.45 (-1.61%)
22-Jun-2017 | 3:58PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 338.00
  • 342.50
  • 330.80
  • 337.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  • 1709306
  • 5676.61
  • 396.00
  • 229.38

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 20,199.00
  • 33.00
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 20,755.40
  • 0.50%
  • 4.01

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.68%
  • 2.05%
  • 11.04%
  • FII
  • DII
  • Others
  • 1.21%
  • 2.51%
  • 22.51%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Var%
Dec 16
Dec 15
Var%
Sep 16
Sep 15
Var%
Jun 16
Jun 15
Var%
Net Sales
931.10
978.80
-4.87%
1,037.60
836.40
24.06%
945.80
837.20
12.97%
982.40
832.99
17.94%
Expenses
743.60
765.70
-2.89%
761.50
647.30
17.64%
705.80
639.54
10.36%
719.30
620.81
15.86%
EBITDA
187.50
213.10
-12.01%
276.10
189.10
46.01%
240.00
197.66
21.42%
263.10
212.18
24.00%
EBIDTM
20.14%
21.77%
26.44%
22.61%
25.15%
23.61%
26.78%
25.47%
Other Income
43.20
24.70
74.90%
47.40
19.70
140.61%
38.40
24.60
56.10%
40.90
23.52
73.89%
Interest
5.00
1.40
257.14%
8.80
1.50
486.67%
6.50
2.93
121.84%
5.70
4.42
28.96%
Depreciation
72.50
62.80
15.45%
70.30
62.10
13.20%
68.30
59.61
14.58%
66.10
57.80
14.36%
PBT
153.20
442.00
-65.34%
244.40
145.20
68.32%
203.60
466.72
-56.38%
232.20
173.48
33.85%
Tax
10.30
58.20
-82.30%
54.40
24.10
125.73%
41.70
137.69
-69.71%
55.20
36.95
49.39%
PAT
142.90
383.80
-62.77%
190.00
121.10
56.90%
161.90
329.03
-50.79%
177.00
136.53
29.64%
PATM
15.35%
39.21%
18.19%
14.48%
16.97%
39.30%
18.02%
16.39%
EPS
2.13
6.01
-64.56%
2.86
1.72
66.28%
2.44
5.10
-52.16%
2.78
2.10
32.38%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Net Sales
3,485.40
3,089.80
2,877.30
2,485.30
2,086.50
1,806.00
2,367.82
1,608.67
1,053.79
985.73
Net Sales Growth
12.80%
7.39%
15.77%
19.11%
15.53%
-23.73%
47.19%
52.66%
6.90%
 
Cost Of Goods Sold
1,329.90
1,255.60
1,186.10
1,044.40
852.00
725.40
1,337.54
838.42
434.62
450.78
Gross Profit
2,155.50
1,834.20
1,691.20
1,440.90
1,234.50
1,080.60
1,030.27
770.25
619.17
534.96
GP Margin
61.84%
59.36%
58.78%
57.98%
59.17%
59.83%
43.51%
47.88%
58.76%
54.27%
Total Expenditure
2,670.10
2,394.00
2,190.20
1,946.30
1,809.30
2,213.40
1,896.33
1,285.31
757.67
712.01
Power & Fuel Cost
194.20
176.70
162.40
142.60
97.20
82.00
67.63
69.33
76.56
61.96
% Of Sales
5.57%
5.72%
5.64%
5.74%
4.66%
4.54%
2.86%
4.31%
7.27%
6.29%
Employee Cost
636.30
533.40
466.30
389.40
307.60
238.80
242.76
179.18
110.68
89.17
% Of Sales
18.26%
17.26%
16.21%
15.67%
14.74%
13.22%
10.25%
11.14%
10.50%
9.05%
Manufacturing Exp.
175.00
81.20
62.90
95.20
113.20
81.60
68.63
66.01
47.71
41.32
% Of Sales
5.02%
2.63%
2.19%
3.83%
5.43%
4.52%
2.90%
4.10%
4.53%
4.19%
General & Admin Exp.
151.50
165.70
131.80
122.20
93.20
82.40
79.09
56.15
38.71
33.18
% Of Sales
4.35%
5.36%
4.58%
4.92%
4.47%
4.56%
3.34%
3.49%
3.67%
3.37%
Selling & Distn. Exp.
113.90
108.70
118.90
99.60
89.40
62.40
56.49
47.67
32.53
23.34
% Of Sales
3.27%
3.52%
4.13%
4.01%
4.28%
3.46%
2.39%
2.96%
3.09%
2.37%
Miscellaneous Exp.
69.30
72.70
61.80
52.90
256.70
940.80
44.19
28.55
16.84
23.34
% Of Sales
1.99%
2.35%
2.15%
2.13%
12.30%
52.09%
1.87%
1.77%
1.60%
1.24%
EBITDA
815.30
695.80
687.10
539.00
277.20
-407.40
471.49
323.36
296.12
273.72
EBITDA Margin
23.39%
22.52%
23.88%
21.69%
13.29%
-22.56%
19.91%
20.10%
28.10%
27.77%
Other Income
89.20
53.10
55.90
56.70
309.40
1,035.50
37.02
64.55
38.88
13.70
Interest
10.20
8.90
1.70
8.10
12.40
24.30
16.89
17.66
10.18
9.88
Depreciation
242.30
221.00
203.60
179.30
175.80
156.70
140.14
110.25
93.92
66.55
PBT
652.00
519.00
537.70
408.30
398.40
447.10
351.47
260.00
230.91
211.00
Tax
256.90
95.70
106.90
97.50
55.90
72.10
48.67
11.84
12.89
16.91
Tax Rate
20.93%
15.33%
19.88%
15.98%
14.03%
16.13%
13.85%
10.50%
2.74%
8.01%
PAT
896.10
497.40
413.80
508.90
341.60
367.50
293.25
93.84
463.91
200.26
PAT before Minority Interest
970.50
528.40
430.80
512.70
342.50
375.00
302.81
100.97
457.39
194.08
Minority Interest
-74.40
-31.00
-17.00
-3.80
-0.90
-7.50
-9.56
-7.13
6.52
6.18
PAT Margin
25.71%
16.10%
14.38%
20.48%
16.37%
20.35%
12.38%
5.83%
44.02%
20.32%
PAT Growth
80.16%
20.20%
-18.69%
48.98%
-7.05%
25.32%
212.50%
-79.77%
131.65%
 
Unadjusted EPS
44.81
24.87
21.09
25.99
17.27
18.79
15.08
4.83
46.39
21.47

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Shareholder's Funds
4,055.60
3,270.60
3,026.70
2,694.60
2,272.40
2,032.80
1,757.85
1,510.74
1,484.15
1,068.61
Share Capital
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
50.00
50.00
Total Reserves
3,904.80
3,132.70
2,806.20
2,491.80
2,079.80
1,850.50
1,595.96
1,369.32
1,397.80
992.55
Non-Current Liabilities
2,487.20
1,377.90
1,262.00
666.30
645.20
455.50
564.44
570.54
301.55
231.60
Secured Loans
2,068.50
758.20
580.40
124.00
9.30
0.00
331.50
395.73
135.04
73.73
Unsecured Loans
3.90
11.40
25.80
40.00
60.50
65.80
182.11
128.18
120.01
113.04
Long Term Provisions
29.90
15.00
7.80
4.00
0.00
1.00
0.00
0.00
0.00
0.00
Current Liabilities
1,627.60
1,554.70
1,379.60
989.90
1,015.80
1,060.60
581.73
438.50
301.42
274.98
Trade Payables
547.10
429.30
347.20
345.50
347.80
296.50
230.86
208.55
172.38
193.70
Other Current Liabilities
597.90
706.20
612.30
313.10
269.20
375.90
260.05
148.42
57.64
38.73
Short Term Borrowings
394.90
261.00
243.50
84.80
187.30
247.40
0.00
0.00
0.00
0.00
Short Term Provisions
87.70
158.20
176.60
246.50
211.50
140.80
90.83
81.53
71.40
42.56
Total Liabilities
8,481.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81
2,544.55
2,079.80
1,574.39
Net Block
1,722.60
1,629.90
1,525.20
1,510.30
1,270.50
1,316.20
1,337.93
1,211.56
931.28
894.90
Gross Block
3,373.00
3,034.20
2,701.70
2,480.90
2,066.20
1,965.80
1,837.13
1,581.70
1,182.39
1,066.11
Accumulated Depreciation
1,650.40
1,404.30
1,176.50
970.60
795.70
649.60
499.20
370.14
251.11
171.21
Non Current Assets
4,488.40
3,812.80
3,111.80
2,176.10
1,937.50
1,779.40
1,460.60
1,422.68
1,101.10
983.50
Capital Work in Progress
2,187.50
1,676.40
1,205.60
312.50
389.50
262.10
75.52
172.02
138.21
70.83
Non Current Investment
0.00
0.00
64.50
64.50
64.20
60.90
47.16
39.10
31.60
17.77
Long Term Loans & Adv.
381.00
336.90
252.00
241.60
181.00
140.20
0.00
0.00
0.00
0.00
Other Non Current Assets
197.30
169.60
64.50
47.20
32.30
0.00
0.00
0.00
0.00
0.00
Current Assets
3,993.20
2,562.60
2,638.80
2,240.00
1,999.70
1,807.20
1,477.21
1,121.87
978.71
590.90
Current Investments
428.50
230.30
700.40
522.10
492.10
399.50
383.42
328.52
443.16
61.31
Inventories
511.40
452.70
376.60
398.40
378.30
413.70
371.64
319.18
178.98
161.32
Sundry Debtors
822.90
770.50
599.80
509.70
491.70
495.80
446.13
366.68
259.13
306.52
Cash & Bank
1,921.30
937.50
804.40
672.90
523.30
441.50
139.93
11.81
9.62
8.73
Other Current Assets
309.10
171.60
157.60
136.90
114.30
56.70
136.10
95.67
87.82
53.01
Short Term Loans & Adv.
185.30
75.80
81.80
81.40
37.10
20.20
120.28
95.05
82.76
51.58
Net Current Assets
2,365.60
1,007.90
1,259.20
1,250.10
983.90
746.60
895.48
683.37
677.28
315.91
Total Assets
8,481.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81
2,544.55
2,079.81
1,574.40

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Cash From Operating Activity
526.40
210.70
560.70
471.20
564.10
798.50
443.81
95.10
317.91
154.76
PBT
1,227.40
624.10
537.70
610.20
395.20
447.10
351.47
104.36
538.66
211.00
Adjustment
-409.40
74.00
134.00
147.30
144.80
163.50
159.65
135.89
-213.83
82.18
Changes in Working Capital
-44.80
-354.00
37.70
-192.30
98.00
269.20
-34.53
-128.21
17.34
-125.19
Cash after chg. in Working capital
773.20
344.10
709.40
565.20
638.00
879.80
476.60
112.04
342.18
167.99
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-246.80
-133.40
-148.70
-94.00
-73.90
-81.30
-32.79
-16.94
-24.27
-13.24
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-954.00
-508.70
-938.10
-375.80
-359.50
-314.50
-226.07
-232.19
-340.15
-191.17
Net Fixed Assets
-270.30
-57.90
-322.80
-213.80
-75.20
-134.97
-55.73
-84.56
-53.65
-118.55
Net Investments
-446.10
328.50
125.80
38.00
-171.10
-67.26
-71.95
130.57
-430.24
92.04
Others
-237.60
-779.30
-741.10
-200.00
-113.20
-112.27
-98.39
-278.20
143.74
-164.66
Cash from Financing Activity
1,086.70
186.20
426.00
-8.60
-186.30
-274.60
-85.21
136.93
23.22
43.09
Net Cash Inflow / Outflow
659.10
-111.80
48.60
86.80
18.30
209.40
132.53
-0.16
0.99
6.68
Opening Cash & Equivalents
462.60
557.00
474.00
369.00
359.00
139.90
11.81
9.62
8.63
1.95
Closing Cash & Equivalent
1,127.00
462.60
557.00
474.00
369.00
359.00
143.10
11.81
9.62
8.63

Financial Ratios

Consolidated /

Standalone
Description
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Book Value (Rs.)
66.73
53.86
48.42
43.18
36.31
32.49
28.25
24.47
24.11
17.36
ROA
13.06%
8.72%
8.47%
12.28%
9.10%
11.50%
11.05%
4.37%
25.03%
13.56%
ROE
26.83%
17.22%
15.68%
21.50%
16.59%
20.58%
19.14%
6.93%
36.76%
20.24%
ROCE
22.67%
15.30%
15.75%
22.47%
16.74%
20.33%
17.12%
6.92%
32.11%
19.67%
Fixed Asset Turnover
1.10
1.09
1.12
1.11
1.06
0.97
1.42
1.19
0.96
1.39
Receivable days
82.64
80.09
69.48
72.22
84.37
93.20
60.98
69.27
95.54
94.69
Inventory Days
50.00
48.47
48.54
56.01
67.67
77.71
51.83
55.14
57.48
48.54
Payable days
65.85
58.15
55.73
65.24
70.25
70.62
41.52
51.80
83.01
95.35
Cash Conversion Cycle
66.79
70.42
62.29
62.99
81.79
100.29
71.30
72.61
70.02
47.88
Total Debt/Equity
0.62
0.35
0.30
0.10
0.12
0.17
0.30
0.36
0.18
0.18
Interest Cover
121.33
71.12
317.29
76.33
33.13
19.40
21.81
7.39
47.20
22.37

News Update


  • Biocon - Quarterly Results
    27th Apr 2017, 12:00 AM

    Read More
  • Biocon enters into collaboration with Ypsomed
    13th Apr 2017, 09:10 AM

    Ypsomed’s customized reusable pen will be marketed by Biocon as INSUPen Pro in Malaysia

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.